Rejuva Fresh® Unveils New Upgrades for Custom CORE™ 8D, a Revolutionary Aesthetic Laser Platform Designed to Transform In-Office Treatments
Rejuva Fresh Custom CORE™ 8D delivers a remarkable advancement in patient personalized care. Featuring eight highly sought-after laser technologies, the platform offers an extensive selection of treatments designed to treat all Fitzpatrick skin types and conditions with precision and success. In fact, more than eighty distinct treatments can be performed with the Custom CORE™ 8D. Indeed, this revolutionary technology brought to market by Rejuva Fresh, is far more versatile in its application compared to competing aesthetic laser platforms, which typically offer fewer options.
Specifically, Rejuva Fresh's revolutionary platform laser features all of the following options: an IPL/BBL, 3 Wavelength-Diode Laser, Pico-Second Laser, Q-Switch Nanosecond Laser, Long Pulsed YAG Laser, and Erbium 1540nm Fractional Laser, 2940nm Erbium YAG, and 808 Diode Laser.
One of the most popular and versatile laser options on Rejuva Fresh Custom CORE™ 8D is the Picosecond Laser, which includes several different attachments and uses ultra-short pulses to create a powerful photoacoustic effects, targeting and breaking down pigment. The Picosecond laser can be successfully used, not only to remove tattoos, but also age spots, acne scars, hyperpigmentation, as well as doing fractional laser skin resurfacing on all skin colors.
Practitioners choosing either the Picosecond or Q Switch Nanosecond laser options on the platform benefit from enhanced collagen stimulation and effective pigmentation treatment by focusing on the skin's deeper layers. Meanwhile, the fractional ablative er:YAG laser gently forms tiny perforations in the skin, promoting renewal while protecting nearby tissue to support faster healing.
And what about painless hair removal? Yes Custom CORE™ 8D does it superbly. In fact, the 3 wave diode laser features 755nm, 808nm, and 1064nm laser bars, offering painless and lasting hair removal for every skin tone. Excitingly, Rejuva Fresh announced that as part of the upgrade unveiling, that now increased power of 1600W as well as 4 interchangeable spot sizes will be available for their diode laser handpieces. This advancement allows for increased precision and significantly more efficiency compared to traditional diode laser systems that feature only one spot size. No need for bulky handle changes, instead effortlessly change the magnetic tips.
The Intense Pulsed Light (IPL)/Broad Band Light (BBL) function has also been upgraded in this recent unveiling. Now the BBL function offers 3 times more energy delivery compared to traditional IPL, as well as 4 interchangeable spot sizes and a facial tip. Rejuva Fresh BBL uses multiple filters to solve different skin concerns, including sun damage, age spots, redness, rosacea, broken blood vessels, fine lines and wrinkles, and uneven pigmentation. With the addition of the flexible spot size the system has become more powerful.
While other platform laser systems would stop there, Rejuva Fresh empowers practitioners to offer even more advanced combinations of skin rejuvenation with 2 powerful Erbium laser options.
Namely, the 2940nm Er:YAG Laser can be used in ablative mode for skin resurfacing and epidermal renewal, or in coagulation mode to stimulate collagen production and improve skin texture. According to Rejuva Fresh clinical esthetician Niki Wu, 'Integrating an Erbium:YAG 2940 nm laser with BBL represents a highly effective strategy in aesthetic dermatology, targeting a range of skin concerns such as pigmentation, texture irregularities, and overall rejuvenation. The combined use of these technologies enhances treatment efficacy by simultaneously addressing multiple dermatological issues.'
Regarding 1540nm Erbium fractional laser, Niki Wu detailed to a group of doctors that the 1540nm laser is a key component of the platform, as it targets deeper skin layers to stimulate collagen production and improve skin texture. 1540nm fractional laser is also very effective to combine with BBL, because the combination addresses both superficial and deeper skin concerns simultaneously.
The Custom CORE™ 8D offers a uniquely balanced approach, and with up to a 65% increase in energy*, this exciting new multiplatform offers the robust capabilities of standalone lasers in a single, sophisticated platform. This enhanced energy enables practitioners to address the diverse needs of patients—across different ages, skin types, and treatment goals—and to provide clinically proven treatments for the most in-demand categories, such as skin resurfacing, skin rejuvenation and tightening, hair removal, acne and acne scars, vascular lesions, pigmented lesions, and tattoo removal, to name a few.
The new Custom CORE™ 8D is engineered to improve efficiency and user-friendliness, featuring advanced automated capabilities like customizable presets, ergonomically crafted applicators, and more seamless operational functionality than ever.
According to Polly Jacobs, founder and CEO of Rejuva Fresh, 'Using several different lights and lasers in one session is the often best way to successfully treat skin conditions, because this approach targets exactly the right skin layers and pigments for better results.'
'Our new Custom CORE™ 8D allows the practitioner to have practically almost the same power as standalone lasers in an all-in-one platform, and to achieve the next level of results with their patients,' she added.
The innovative platform is FDA cleared and according to Jacobs: 'After years of development, we are proud to introduce Custom CORE™ 8D to the global market. Combining cutting-edge technology with innovative design, every detail has been meticulously crafted, and we aim to offer a seamless and intelligent user experience'
Custom CORE™ 8D raises the bar for functionality, versatility, and performance. This new multiplatform enables professionals to integrate complementary technologies, effectively treating a broad spectrum of aesthetic concerns. It meets the increasing demand for combination procedures that provide longer-lasting results and faster recovery, while significantly improving both practitioner efficiency and patient satisfaction.
To help clinics further expand their services and boost visibility, Rejuva Fresh is introducing the new Custom CORE™ 8D Platform alongside its new line of organic serums for their Rejuva Fresh Hydra Spa Infusion Ultra Glow—an exceptionally popular effective branded treatment addressing the highly sought-after skin rejuvenation market.
Rejuva Fresh Hydra Spa Infusion Ultra Glow, is a comprehensive treatment that harnesses the skin's natural healing process and leverages the powers of hydro dermabrasion, oxygen therapy, bio stimulation, radio frequency, ultrasound and more to deliver enhanced results. This treatment is arguably more advanced and effective than the traditional Hydra Facial MD as it enables improvement in skin tone and texture as well as hydration deep cleansing and exfoliation. It also serves as a catalyst for collagen renewal and elastin production that continues to work for months post-treatment.
*Compared to competing laser platforms such as Harmony XL PRO or Lumenis M22 using specific parameters
About Rejuva Fresh, LLC.
Rejuva Fresh® is a leading aesthetic equipment developer based in the United States and prioritizes offering powerful state-of-the-art technology combined with top-notch customer support. One of the fastest-growing companies in the aesthetic device industry, Rejuva Fresh offers a wide selection of FDA-cleared systems that address nearly every non-invasive aesthetic and wellness need. Rejuva Fresh's product portfolio provides significant competitive advantages for practices and patients, thanks to their independent business model and strong partnerships with top factories worldwide. Invest in Rejuva Fresh scientifically developed devices, and get comprehensive support from industry experts to achieve optimal clinical results and maximize your return on investment.
For more information, visit: www.rejuvafresh.com.
Media Contact:Ericson Estrada[email protected] 1-888-436-3120
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
6 hours ago
- Malaysian Reserve
BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
Study Will Compare Four Amnion-Based Therapies Plus Standard of Care to Standard of Care Alone in Chronic Wound Management PHOENIX, July 31, 2025 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in regenerative wound care, has initiated its most comprehensive clinical trial to date. The multicenter, prospective, randomized controlled study will evaluate the efficacy of four human placental membrane (HPM) products in combination with standard of care (SOC) compared to SOC alone in the treatment of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The trial, formally titled 'A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP),' will enroll 650 subjects across up to 30 clinical sites nationwide. 'This study represents a major milestone in our commitment to advancing wound care through rigorous clinical research,' said Dr. Marshall Medley, chief medical officer at BioLab. 'By evaluating our full suite of amnion-based products in a real-world setting, we aim to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds.' Participants will be randomized to receive one of four BioLab products—Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4)—in addition to SOC, or SOC alone. Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed two weeks later. Optional weekly visits will allow for dressing changes in both study arms. The study is designed to capture real-world clinical outcomes and support the growing body of evidence for the use of placental-derived allografts in chronic wound management. For more information on BioLab Holdings, Inc. and its regenerative wound care solutions, visit About BioLab Holdings, Holdings, Inc. is a Phoenix-based medical manufacturer focused on wound healing and regenerative medicine. Its product portfolio includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™, all derived from human amniotic membrane. These minimally manipulated allografts are designed to preserve the tissue's natural properties and support healing. BioLab is committed to delivering safe, high-quality products through innovation, education and exceptional customer service. Learn more at Contact: Kwyn LowePhone: 406.314.5120Email: kwyn@
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Dana Incorporated to Announce 2025 Second-quarter Financial Results, Host Conference Call and Webcast on August 5
MAUMEE, Ohio, July 31, 2025 /PRNewswire/ — Dana Incorporated (NYSE: DAN) will release its 2025 second-quarter financial results on Tuesday, August 5, 2025. A press release will be issued at approximately 7 a.m. EDT, followed by a conference call and webcast at 9 a.m. EDT. Members of the company's senior management team will be available at that time to discuss the results and answer related questions. The conference call can be accessed by telephone from both domestic and international locations using the information provided below: Conference ID: 9943139Participant Toll-Free Dial-In Number: 1 (888) 440-5873Participant Toll Dial-In Number: 1 (646) 960-0319 Audio streaming and slides will be available online via a link provided on the Dana investor website: A webcast replay can be accessed via Dana's investor website following the call. About Dana IncorporatedDana is a leader in the design and manufacture of highly efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company is shaping sustainable progress through its conventional and clean-energy solutions that support nearly every vehicle manufacturer with drive and motion systems; electrodynamic technologies, including software and controls; and thermal, sealing, and digital solutions. Based in Maumee, Ohio, USA, the company reported sales of $10.3 billion in 2024 with 39,000 people in 30 countries across six continents. With a history dating to 1904, Dana was named among the 'World's Most Ethical Companies' for 2025 by Ethisphere and as one of 'America's Most Responsible Companies 2025' by Newsweek. The company is driven by a high-performance culture that focuses on valuing others, inspiring innovation, growing responsibly, and winning together, earning it global recognition as a top employer. Learn more at
Malaysian Reserve
6 hours ago
- Malaysian Reserve
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) witho
FDA approval is based on phase 3 trial data (explorer8), which established the safety and efficacy of Alhemo® (concizumab-mtci) injection in people 12 years and older with hemophilia A or B (HA/HB) without inhibitors1 Results showed a 79% reduction in annualized bleeding rate (ABR) in patients with HB without inhibitors and an 86% reduction in patients with HA without inhibitors, respectively, using Alhemo® prophylaxis compared to no prophylaxis2 Alhemo® was the first subcutaneous injectable pen of its kind for patients living with HA and HB with inhibitors and is now approved for those living without inhibitors1 PLAINSBORO, N.J., July 31, 2025 /PRNewswire/ — Novo Nordisk announced today that the US Food and Drug Administration (FDA) approved Alhemo® (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors, expanding on the December 2024 approval for HA/HB with inhibitors.1,2,3 Currently, many treatments for HA/HB without inhibitors are administered via intravenous infusions.2 With this approval, Alhemo® now offers a subcutaneous injection treatment option for this population.1 'The FDA approval of an expanded indication for Alhemo® marks a meaningful step forward for people with hemophilia A or B without inhibitors who are looking for a new prophylaxis treatment option,' said Anna Windle, PhD, Senior Vice President, Clinical Development, Medical & Regulatory Affairs, Novo Nordisk. 'By building on the initial indication for Alhemo® for those with hemophilia with inhibitors—an especially significant development in hemophilia B where challenges still exist despite advanced treatment options—Novo Nordisk continues its 35+ year legacy in rare bleeding disorders to continue to help address the unmet needs of this community.' Alhemo® is designed to block a protein called tissue factor pathway inhibitor (TFPI), which stops blood from clotting. By inhibiting TFPI, Alhemo® improves the production of thrombin, which helps to clot the blood and prevent bleeding, when clotting factors VIII and IX are missing or deficient regardless of inhibitor status.4,5 'For people living with hemophilia, it is important to continually monitor and discuss bleed control with their healthcare professional,' said Allison P. Wheeler, MD, Scientific Director, Washington Center for Bleeding Disorders, Seattle, WA. 'With today's approval of Alhemo® for hemophilia A or B without inhibitors, more people living with these rare blood disorders now have a daily prophylaxis option that may help decrease their bleeding rates.' The primary objective of the pivotal phase 3 explorer8 trial was to compare the number of treated spontaneous and traumatic bleeding episodes, as measured by the ABR, in patients aged 12 years and older with HA/HB without inhibitors, receiving Alhemo® prophylaxis versus no prophylaxis (on demand Factor VIII/Factor IX treatment).2 The study showed a statistically significant reduction in ABR of 79% for HB patients (ABR ratio: 0.21; 95% CI: 0.10–0.45; p<0.0001) and 86% for HA patients (ABR ratio: 0.14; 95% CI: 0.07–0.29; p<0.0001). Additionally, notable reductions in the average and median ABRs further reinforced the efficacy of Alhemo® prophylaxis in reducing bleeds across both patient groups, with an average ABR of 3.1 (1.9-5.0) and a median ABR of 1.6 (0.0-4.8) for HB patients, compared to 14.8 (8.1-26.9) and 14.9 (3.3-22.1), respectively, and an average ABR of 2.7 (1.6-4.6) and median ABR of 2.9 (0.0-5.2) for HA patients, compared to 19.3 (11.3-33.0) and 19.6 (17.3-30.4), respectively. In the study, the most common adverse reactions reported in ≥5% of patients randomized to receive Alhemo® were injection site reactions (7%) and headache (7%).1 Alhemo® is provided in prefilled, premixed pens for subcutaneous injection (60 mg/1.5 mL, 150 mg/1.5 mL, or 300 mg/3 mL) via thin 32 gauge, 4 mm needles, which are provided separately, offering an additional treatment choice for patients with hemophilia with inhibitors – and now without inhibitors – to further customize their care. About the explorer8 studyExplorer8 is a phase 3 clinical trial that evaluated the efficacy and safety of Alhemo® for adults and pediatric patients 12 years of age and older living with hemophilia A or B (HA/HB) without inhibitors.2 In explorer8, among the 156 males with HA/HB included in the trial, 63 were randomly assigned in a 1:2 ratio to receive no prophylaxis (arm 1, n=21), or Alhemo® prophylaxis (arm 2, n=42).2,6 The median duration of treatment was 24.1 weeks in arm 1 (no prophylaxis) and 32.1 weeks in arm 2 (Alhemo® prophylaxis).The initial loading dose of Alhemo® was 1 mg per kilogram of body weight, followed by 0.2 mg per kilogram daily, and potentially individualized on the basis of concizumab-mtci plasma concentration as measured at week 4.1,2 Efficacy was evaluated separately in HA patients without inhibitors and in HB patients without inhibitors when all patients in arms 1 and 2 had completed the main part of the trial (at least 24 or at least 32 weeks, respectively), based on the number of treated bleeding episodes comparing Alhemo® prophylaxis and no prophylaxis.1 About Alhemo® (concizumab-mtci) Alhemo® is a tissue factor pathway inhibitor (TFPI) antagonist. By inhibiting the TFPI, Alhemo® enhances factor Xa (FXa) production during the initiation phase of coagulation, leading to improved thrombin generation and clot formation in patients with hemophilia A or B (HA/HB) with or without inhibitors. The effect of Alhemo® is not influenced by the presence of inhibitory antibodies to FVIII or FIX and Alhemo® does not induce or enhance the development of direct inhibitors to FVIII or FIX. Alhemo® is approved as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with HA/HB with or without inhibitors in the US.1 What is Alhemo®?Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with or without factor VIII or IX inhibitors. It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age Important Safety Information What is the most important information I should know about Alhemo®? It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding Your HCP may prescribe factor VIII, factor IX, or bypassing agents during treatment with Alhemo®. Carefully follow your HCP's instructions regarding when to use on-demand factor VIII, factor IX, or bypassing agents and the recommended dose and schedule for breakthrough bleeds Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®. Before using Alhemo®, tell your HCP about all of your medical conditions, including if you: Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery Are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk Your HCP may do a pregnancy test before you start treatment with Alhemo® Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment Your HCP may do a pregnancy test before you start treatment with Alhemo® Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements. What are the possible side effects of Alhemo®?Alhemo® may cause serious side effects, including: Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat The most common side effects of Alhemo® include: bruising, redness, bleeding, itching, rash or lump at the injection site, headache, and hives. These are not all the possible side effects of Alhemo®. Call your doctor for medical advice about side effects. Please click HERE for Alhemo® Prescribing Information and Medication Guide About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.7 It is estimated to affect approximately ~800,000 people worldwide.8 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing. Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX (FIX).7 Hemophilia is often treated by replacing the missing clotting factor via intravenous infusions, also known as replacement therapy.8 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. References Alhemo® (concizumab-mtci) injection, for subcutaneous use [package insert]. Plainsboro, NJ: Novo Nordisk Inc. Chowdary P., et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Hematology. 2024;11:e891-904. Novo Nordisk. FDA approves drug to prevent or reduce the frequency of bleeding episodes for patients with hemophilia A with inhibitors or hemophilia B with inhibitors. Accessed May 2025. Available at Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv. 2021;5(1):279. Matsushita T, Shapiro A, Abraham A, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023; 389(9): 783-794. Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8). Accessed May 2025. Available at MedlinePlus. Hemophilia. Accessed May 2025. Available at World Federation of Hemophilia. Annual Global Survey 2023. Accessed July 2025. Further information Liz Skrbkova (US)+1 609 917 0632 (Mobile)USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Alhemo® is a registered trademark of Novo Nordisk Health Care AG. Novo Nordisk is a registered trademark of Novo Nordisk A/S.© 2025 Novo Nordisk All rights reserved. US25AHM00187 July 2025
